Clinical Trial Update: Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED). [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on GRF312 5% for Dry Eye Disease, currently recruiting to evaluate safety, tolerability, and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• GRF312 5%

Snippet

Sponsor: Instituto Grifols, S.A. | Conditions: Dry Eye Disease | Phase 2 | Status: RECRUITING